Fed. Circ. Backs Novartis In Kidney Cancer Drug Patent Case
The Federal Circuit on Monday upheld a lower court's ruling that a Novartis patent on the kidney cancer drug Afinitor is not invalid as obvious, giving the company a win in...To view the full article, register now.
Already a subscriber? Click here to view full article